Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double Blind, Randomized Placebo Controlled Clinical Trial Investigating the Efficacy and Safety of Somatuline Depot (Lanreotide) Injection in the Treatment of Carcinoid Syndrome

NCT00774930 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT00774930
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00774930 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double Blind, Randomized Placebo Controlled Clinical Trial Investigating the Efficacy and Safety of Somatuline Depot (Lanreotide) Injection in the Treatment of Carcinoid Syndrome
Lead sponsor
Ipsen
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2009
Completion date
December 31, 2015
Enrollment
115 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoid syndrome